Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease

Fineline Cube Apr 1, 2026
Company Drug

Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy

Fineline Cube Apr 1, 2026
Company Drug

Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC

Fineline Cube Feb 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...

Company Deals

Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m

Fineline Cube Feb 17, 2025

Tianyi Medical (SHE: 301097), a Ningbo-based developer of Class III medical consumables, has announced plans...

Company Drug

Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents

Fineline Cube Feb 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase...

Company Drug

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval

Fineline Cube Feb 17, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the submission of a marketing filing for...

Company

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology

Fineline Cube Feb 16, 2025

In a move that has sent ripples through China’s vaccine industry, Changchun BCHT Biotechnology Co.,...

Company

Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing

Fineline Cube Feb 15, 2025

Beijing Wanjie Medical Device Co., Ltd. recently announced the successful completion of a B-round financing...

Company Digital

Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains

Fineline Cube Feb 15, 2025

On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector,...

Company

LinkZill Completes Multi-Million-Dollar A-Round Financing Led by ProximaVentures

Fineline Cube Feb 14, 2025

Hangzhou LinkZill Technology Co., Ltd. has recently completed a multi-million-dollar A-round financing, exclusively led by...

Policy / Regulatory

New Guidelines for Advanced Gastric Cancer Drug Development Released in China

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) of China has published the “Guidance Principles for Clinical...

Company Drug

Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study

Fineline Cube Feb 14, 2025

US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study...

Company Drug

Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment

Fineline Cube Feb 14, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...

Company

GE Healthcare Posts 1% Annual Revenue Growth in 2024 Financials

Fineline Cube Feb 14, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) released its...

Company Drug

Betta Pharma Files for EMA Approval of ALK Inhibitor Ensartinib

Fineline Cube Feb 14, 2025

Betta Pharmaceuticals (SHE: 300558) announced the initiation of a market approval filing with the European...

Company Deals Drug

Lee Kai and Yangshun Partner on Polyvinyl Alcohol Embolization Microspheres

Fineline Cube Feb 14, 2025

Chinese companies Shanghai Lee Kai Technology Co., Ltd (Kai Medtech) and Hangzhou Yangshun Medical Technology...

Company Deals

Nanos Medical Raises Over RMB300m to Boost Otolaryngology Device Lead

Fineline Cube Feb 14, 2025

China-based Nanos Medical (Shanghai) Limited, an otolaryngology device maker, has reportedly raised over RMB300 million...

Company Drug

SciClone’s Vibativ Approved by NMPA for HABP/VABP Treatment

Fineline Cube Feb 14, 2025

China-based SciClone Pharmaceuticals Inc. announced that it has received market approval from the National Medical...

Company Deals

Trinomab’s Antitetanus mAb Injection TNM002 Approved by NMPA

Fineline Cube Feb 14, 2025

China-based Trinomab Biotech Co., Ltd has received market approval for its antitetanus toxin monoclonal antibody...

Policy / Regulatory

NMPA Releases 90th Batch of Reference Drugs for GQCE

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) has released the 90th batch of reference drugs for...

Company Drug

Accropeutics Doses First Patient in AC-101 Phase Ib UC Study

Fineline Cube Feb 14, 2025

Accro Bioscience (Suzhou) limited, better known as Accropeutics, a clinical-stage biotech operating out of New...

Policy / Regulatory

China Launches Major Public Health Initiatives to Enhance Healthcare Accessibility

Fineline Cube Feb 14, 2025

In a bid to bolster public health infrastructure and improve healthcare services, China’s National Health...

Posts pagination

1 … 191 192 193 … 644

Recent updates

  • Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease
  • Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition
  • Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform
  • Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy
  • AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease

Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Company Drug

Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.